Since some studies reported that HER2 mediates tumor growth and metastasis [33, 34], and several molecular changes (that could alter tumor aggressiveness) occurred on HER2 and its downstream pathways, we conducted experiments to evaluate such hallmark by measuring cell invasion and adhesion to extracellular matrix (opening metastatic event) capacities of our developed resistant cells (Fig 1E). Here, ERBB2 is linked to neoplasm.